plans – Talk Bio

Actionable Insights Powered by AI

Aspen Neuroscience Secures $115 Million Series C to Advance Parkinson’s Cell Therapy; IPO Considered for 2026

3 weeks ago talkbio0Tagged Aspen, Bach Flower Essence, Autologous (qualifier value), Cell Therapy, Clinical Trials, Induced Pluripotent Stem Cells, IPO, manufacturing scale-up, Neuroscience discipline, Parkinson 's disease, plans, Regenerative Medicine, Series C financing

Aspen Neuroscience; Series C financing; Parkinson’s disease; cell therapy; ANPD001; autologous iPSC; clinical trials; manufacturing scale-up; IPO plans; regenerative medicine

Rapport, a J&J Neuroscience Spinout, Prepares for Summer IPO as the First Biotech of the Season

2 years ago talkbio0Tagged IPO, J&J, Neuroscience discipline, plans, Rapport, Summer, Third Rock

Rapport, IPO, J&J, neuroscience, biotech, summer plans, Third Rock.